Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2014-08-01 / Int J Hyperthermia 2014 Aug;30(5):285-94Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis
/in Breast Cancer, Dendritic Cells, International Publications /von 2014-05-01 / Cytotherapy 2014 Jul;16(7):934-45Dendritic cell-based vaccines: clinical applications in breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2014-01-01 / Immunotherapy 2014;6(3):349-60[The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]
/in Breast Cancer, Hyperthermia, International Publications /von 2013-11-01 / Gan To Kagaku Ryoho 2013 Nov;40(12):1596-9Dendritic cells, inflammation, and breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-6Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
/in Breast Cancer, Dendritic Cells, International Publications /von 2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-9Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS
/in Breast Cancer, Dendritic Cells, International Publications /von 2013-07-13 / Ann. Surg. Oncol. 2013 Oct;20(10):3233-9Re-irradiation and hyperthermia after surgery for recurrent breast cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2013-06-03 / Radiother Oncol 2013 Nov;109(2):188-93Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel
/in Breast Cancer, Hyperthermia, International Publications /von 2012-12-11 / Biol. Pharm. Bull. 2013;36(3):376-83
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution